Drug-eluting stents: Preventing restenosis

Cardiology in Review

Volumn 15, Issue 1, 2007, Pages 1-12

  Slavin, Leo ^a   Chhabra, Ankush ^a   Tobis, Jonathan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Paclitaxel; Percutaneous transluminal coronary angioplasty; Restenosis; Sirolimus; Stents

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; POLYMER; RAPAMYCIN;

ATHEROSCLEROSIS; BRACHYTHERAPY; BREAST CARCINOMA; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG COATING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTIMA; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; SWINE;

EID: 33845751988     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000200844.16899.fc     Document Type: Review

References (94)

1. AHA/ACC Clinical Performance Measures: Chronic Stable Coronary Artery Disease. 2003:1-8.
2. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39:183-193.
3. Schwartz RS. Animal models of human coronary restenosis. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd ed. Philadelphia: WB Saunders Co; 1994:365-381.
4. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-495.
5. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
6. Holmes DR Jr, Vliestra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77C-81C.
7. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
8. Kimura T, Kaburagi S, Tashima Y, et al. Geometric remodeling and intimal regrowth as mechanisms of restenosis: observations from serial ultrasound analysis of restenosis (SURE) trial. Circulation. 1995;92:I-76.
9. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-706.
10. Gould K, Lipscomb K, Hamilton GW. Physiological basis for assessing critical coronary stenosis: instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974;33:87-94.
11. Garas SM, Huber P, Scott NA. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther. 2001;92:165-178.
12. Rensing BJ, Hermans WR, Beatt KJ, et al. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;66:1039-1044.
13. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 1996;93:2178-2187.
14. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med. 2002;3:S4-S9.
15. Grant MB, Wargovich TJ, Ellis EA, et al. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation. 1994;89:1511-1517.
16. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86(suppl 6):III43-III46.
17. Castellot JJ Jr, Addonizio ML, Rosenberg R, et al. Cultured endothelial cells produce heparin-like inhibitor of smooth muscle growth. J Cell Biol. 1981;90:372-377.
18. Indolfi C, Mongiardo A, Curcio A. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med. 2003;13:142-148.
19. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. Inhibition of cellular RAS prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;6:541-545.
20. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase. Basic Res Cardiol. 1997;92:378-384.
21. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000;35:157-163.
22. Wilcox JN, Waksman R, King SB, et al. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Biol Phys. 1996;36:789-796.
23. Kuntz RE, Gibson CM, Nobuyoshi M, et al. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25.
24. Gordon PC, Gibson CM, Cohen DJ, et al. Mechanisms of restenosis and redilation within coronary stents - quantitative angiographic assessment. J Am Coll Cardiol. 1993;21:1166-1174.
25. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247-1254.
26. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-230.
27. Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000;356:1895-1897.
28. Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation. 2000;102:523-530.
29. Bittl JA, Chew DP, Topol EJ, et al. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. J Am Coll Cardiol. 2004;43:936-942.
30. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, et al. Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicenter, prospective, randomized study. The DISCO trial. Eur Heart J. 2002;23:633-640.
31. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduced neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 2000;36:1529-1535.
32. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106:1243-1250.
33. Walter DH, Schachinger V, Elsner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol. 2000;85:962-968.
34. Tanabe Y, Ito E, Nakagawa I. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 2001;78:285-291.
35. Kozuma K, Hara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124-130.
36. Park S, Lee CW, Kim H, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499-503.
37. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation. 2000;102:951-958.
38. Sabate M, Pimentel G, Prieto C, et al. Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. J Am Coll Cardiol. 2004;44:520-527.
39. Coen V, Serruys P, Sauerwein W, et al. Reno, a European postmarket surveillance registry, confirms effectiveness of coronary brachytherapy in routine clinical practice. Int J Radiat Oncol Biol Phys. 2003;55:1019-1026.
40. Amols HI, Zaider M, Weinberger J, et al. Dosimetric consideration for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys. 1996;36:913-921.
41. Sabate M, Costa MA, Kozuma K, et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation. 2000;103:E65-E66.
42. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-2295.
43. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
44. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3-16.
45. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
46. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193.
47. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
48. Sousa JE, Costa MA, Abizaid A, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
49. Sousa JE, Costa MA, Sousa A, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation. 2003;107:381-383.
50. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasound follow-up. Eur Heart J. 2001;22:2125-2130.
51. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation. Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-1613.
52. Morice MC, Serruys P, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
53. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. Three-year results of the RAVEL trial. Circulation. 2005;111:1040-1044.
54. Moses JW, Leon MB, Pompa JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
55. Leon MB for the SIRIUS Trial Investigators. Long-term clinical benefit of CYPHER sirolimus-eluting coronary stents: 3-year follow-up of the SIRIUS study. Presented at the 54th Annual Scientific Session of the American College of Cardiology; March 2005; Orlando, FL.
56. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
57. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115.
58. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-1014.
59. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-479.
60. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
61. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
62. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
63. TAXUS IV US Pivotal Trial data at 24-months. Available at: http://www.bostonscientific.com.
64. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA. 2005;294:1215-1223.
65. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
66. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent (ELUTES). Circulation. 2004;109:487-493.
67. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-1954.
68. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. J Am Coll Cardiol. 2005;45:308-311.
69. Morice MC, for the REALITY Trial Investigators. REALITY: a prospective, randomized, multi-center comparison study of the CYPHER sirolimus-eluting and TAXUS paclitaxel-eluting stent systems. Presented at the 54th Annual Scientific Session of the American College of Cardiology; March 2005; Orlando, FL.
70. Windecker S, Remondino A, Eberli F, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662.
71. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-171.
72. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670.
73. Serruys PW. Arterial revascularization therapies study part II of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. Presented at the 54th Annual Scientific Session of the American College of Cardiology; March 2005; Orlando, FL. Abstract 1058-6.
74. Vik-Mo H, Wiseth R, Hegbom K. Coronary aneurysm after implantation of a paclitaxel-eluting stent. Scand Cardiovasc J. 2004;38:349-352.
75. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Clopidogrel for the reduction of events during observation. JAMA. 2002;288:2411-2420.
76. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
77. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932.
78. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial. In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-564.
79. Babapulle MH, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet. 2004;364:583-591.
80. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. JAMA. 2005;293:2109-2117.
81. Lemos PA, Saia F, Hofma S, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:704-708.
82. Melikian N, Airoldi F, Di Mario C. Coronary bifurcation stenting. Current techniques, outcomes and possible future developments. Minera Cardioangiol. 2004;52:365-378.
83. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244-1249.
84. Pan M, Suarez de Lezo J, Medina A, et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J. 2004;148:857-864.
85. Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique. Importance of final kissing balloon post-dilation. J Am Coll Cardiol. 2005;46:613-620.
86. Ge L, Tsagalou E, Iakovou I, et al. In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. Am J Cardiol. 2005;95:757-760.
87. Valgimigli M, van Mieghem CAG, Ong AT, et al. Short- and long-term clinical outcomes after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. Circulation. 2005;11:1383-1389.
88. Arampatzis CA, Lemos PA, Hoye A, et al. Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-months angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv. 2004;62:292-296.
89. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation. 2005;111:791-795.
90. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents. J Am Coll Cardiol. 2005;45:989-994.
91. Cohen DJ, Breall JA, Ho KK, et al. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol. 1993;22:1052-1059.
92. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomized trials. JAMA. 2005;294:819-825.
93. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
94. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation. 2003;107:3003-3007.